NCT02939742

Brief Summary

The purpose of this study is to determine if a repeat course of betamethasone given to pregnant women with preterm premature rupture of membranes (PPROM) will decrease the infant's length of stay in the neonatal intensive care unit (NICU) and the overall neonatal morbidity associated with this condition.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Nov 2016

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 23, 2016

Completed
27 days until next milestone

First Posted

Study publicly available on registry

October 20, 2016

Completed
12 days until next milestone

Study Start

First participant enrolled

November 1, 2016

Completed
7.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2023

Completed
Last Updated

January 26, 2024

Status Verified

January 1, 2024

Enrollment Period

7.1 years

First QC Date

September 23, 2016

Last Update Submit

January 24, 2024

Conditions

Keywords

preterm premature rupture of membranescomplications of prematurityneonatal morbidityrespiratory distress syndromeantenatal corticosteroidsbetamethasone

Outcome Measures

Primary Outcomes (1)

  • Length of stay in the neonatal intensive care unit (NICU)

    expressed in days

    daily from birth of infant up to one year

Secondary Outcomes (7)

  • Composite neonatal morbidity

    assessed daily up to 120 days after birth or discharge from hospital, whichever occurs first

  • Duration of oxygen and ventilatory support

    assessed daily up to 120 days after birth or discharge from hospital, whichever occurs first

  • Development of Respiratory Distress Syndrome (RDS)

    assessed daily up to 120 days after birth or discharge from hospital, whichever occurs first

  • Grade III or IV intraventricular hemorrhage (IVH)

    assessed daily up to 120 days after birth or discharge from hospital, whichever occurs first

  • Neonatal Sepsis

    daily up to 72 hours of life

  • +2 more secondary outcomes

Other Outcomes (2)

  • Labor latency

    time from admission to delivery up to one year, or through study completion

  • Infectious morbidities

    time from admission until maternal discharge from the hospital and up until 6 weeks postpartum, or through study completion

Study Arms (2)

Betamethasone

EXPERIMENTAL

Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.

Drug: Betamethasone

Saline Placebo

PLACEBO COMPARATOR

Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.

Drug: Placebo

Interventions

Betamethasone 12mg IM given every 24 hours for two doses

Also known as: Celestone
Betamethasone

Sterile 0.9% normal saline solution given IM every 24 hours for two doses

Also known as: Saline placebo
Saline Placebo

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Maternal age ≥ 18 years
  • Preterm premature rupture of membranes, demonstrated clinically by speculum exam
  • Cervical dilation visually ≤ 5cm on sterile speculum exam
  • Planned delivery at John Sealy Hospital (JSH)
  • Gestational age of membrane rupture and initiation of first course of antenatal corticosteroids between 23 5/7 - 32 5/7 weeks
  • Planned pregnancy continuation with no indication for delivery for at least 7 days

You may not qualify if:

  • Maternal age \> 50 years
  • Gestational age \< 23 5/7 weeks or \> 32 5/7 weeks
  • Known major congenital abnormalities, aneuploidy, or genetic syndrome
  • Intrauterine fetal demise
  • Any indication for expedited delivery
  • Maternal chorioamnionitis
  • Known allergy or adverse reaction to corticosteroids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Texas Medical Branch in Galveston

Galveston, Texas, 77555, United States

Location

Related Publications (10)

  • Atarod Z, Taghipour M, Roohanizadeh H, Fadavi S, Taghavipour M. Effects of single course and multicourse betamethasone prior to birth in the prognosis of the preterm neonates: A randomized, double-blind placebo-control clinical trial study. J Res Med Sci. 2014 Aug;19(8):715-9.

    PMID: 25422655BACKGROUND
  • Brookfield KF, El-Sayed YY, Chao L, Berger V, Naqvi M, Butwick AJ. Antenatal corticosteroids for preterm premature rupture of membranes: single or repeat course? Am J Perinatol. 2015 May;32(6):537-44. doi: 10.1055/s-0034-1396690. Epub 2014 Dec 29.

    PMID: 25545441BACKGROUND
  • Elimian A, Verma U, Canterino J, Shah J, Visintainer P, Tejani N. Effectiveness of antenatal steroids in obstetric subgroups. Obstet Gynecol. 1999 Feb;93(2):174-9. doi: 10.1016/s0029-7844(98)00400-1.

    PMID: 9932550BACKGROUND
  • Elimian A, Verma U, Visintainer P, Tejani N. Effectiveness of multidose antenatal steroids. Obstet Gynecol. 2000 Jan;95(1):34-6. doi: 10.1016/s0029-7844(99)00471-8.

    PMID: 10636498BACKGROUND
  • Gyamfi-Bannerman C, Son M. Preterm premature rupture of membranes and the rate of neonatal sepsis after two courses of antenatal corticosteroids. Obstet Gynecol. 2014 Nov;124(5):999-1003. doi: 10.1097/AOG.0000000000000460.

    PMID: 25437730BACKGROUND
  • Mazumder P, Dutta S, Kaur J, Narang A. Single versus multiple courses of antenatal betamethasone and neonatal outcome: a randomized controlled trial. Indian Pediatr. 2008 Aug;45(8):661-7.

    PMID: 18723909BACKGROUND
  • National Institutes of Health Consensus Development Panel. Antenatal corticosteroids revisited: repeat courses - National Institutes of Health Consensus Development Conference Statement, August 17-18, 2000. Obstet Gynecol. 2001 Jul;98(1):144-50. doi: 10.1016/s0029-7844(01)01410-7.

    PMID: 11430973BACKGROUND
  • Practice bulletins No. 139: premature rupture of membranes. Obstet Gynecol. 2013 Oct;122(4):918-930. doi: 10.1097/01.AOG.0000435415.21944.8f.

    PMID: 24084566BACKGROUND
  • Wijnberger LD, Mostert JM, van Dam KI, Mol BW, Brouwers H, Visser GH. Comparison of single and repeated antenatal corticosteroid therapy to prevent neonatal death and morbidity in the preterm infant. Early Hum Dev. 2002 Apr;67(1-2):29-36. doi: 10.1016/s0378-3782(01)00248-1.

    PMID: 11893433BACKGROUND
  • Yang SH, Choi SJ, Roh CR, Kim JH. Multiple courses of antenatal corticosteroid therapy in patients with preterm premature rupture of membranes. J Perinat Med. 2004;32(1):42-8. doi: 10.1515/JPM.2004.007.

    PMID: 15008385BACKGROUND

MeSH Terms

Conditions

Preterm Premature Rupture of the MembranesRespiratory Distress Syndrome In Premature InfantsRespiratory Distress Syndrome

Interventions

Betamethasone

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiration Disorders

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Officials

  • Benjamin Bush, MD

    University of Texas Medical Branch in Galveston

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 23, 2016

First Posted

October 20, 2016

Study Start

November 1, 2016

Primary Completion

December 20, 2023

Study Completion

December 20, 2023

Last Updated

January 26, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

Locations